Cathie Wood’s ARK ETFs have released their daily trade report for Tuesday, 22 July 2025, showcasing a series of strategic buy ...

New integration brings Guardant Health's complete oncology testing portfolio into the VieCure Halo Intelligence platform, streamlining access to precision diagnostics at the point of care DENVER ...

Browse 416 market data Tables and 92 Figures spread through 445 Pages and in-depth TOC on "Precision Diagnostics & Medicine Market by Diagnostic Testing (Genetic, DTC), Diagnostics Indication ...

Guardant Health’s first quarter results were shaped by strong growth in both its oncology and screening businesses, with management crediting product upgrades and increasing test volumes as key ...

LIBERATE Study: Guardant Reveal showed high sensitivity and 100% positive predictive value for relapse The LIBERATE study retrospectively analyzed 290 blood samples from 95 patients who were ...

PALO ALTO, Calif., June 09, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open.The results in the peer-reviewed manuscript ...

"With the Guardant Reveal test, a simple blood draw can be used to identify colorectal cancer patients who have molecular residual disease and are most likely to benefit from adjuvant therapy ...

In Largest Molecular Residual Disease (MRD) Study in Colon Cancer, Guardant Reveal Testing Prior to Chemotherapy Provides Robust Stratification for Risk of Disease Recurrence and Survival to ...

Guardant Reveal has seen strong uptake in breast cancer already, and we have additional publications of breast data and IO monitoring data this year that will help to further unlock demand and ...